PSA screening for prostate cancer: why so much controversy? - Wikidata - wikimedia - TriplyDB

PSA screening for prostate cancer: why so much controversy?

PSA screening for prostate cancer: why so much controversy?

http://www.wikidata.org/entity/Q37436987

about

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Toll-Like Receptor 4 (TLR4)/Cyclooxygenase-2 (COX-2) Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion by NF-κB Activation

P2860

Q43169980-692EA32E-07AC-424F-AD08-EBC09FCD6D66 Q58788075-B8B435A2-6AE4-4B5F-B4D9-D8D51D7D5F7B

P2860

PSA screening for prostate cancer: why so much controversy?

http://www.wikidata.org/entity/Q37436987

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PSA screening for prostate cancer: why so much controversy?

@en

PSA screening for prostate cancer: why so much controversy?

@nl

type

label

PSA screening for prostate cancer: why so much controversy?

@en

PSA screening for prostate cancer: why so much controversy?

@nl

prefLabel

PSA screening for prostate cancer: why so much controversy?

@en

PSA screening for prostate cancer: why so much controversy?

@nl

P1433

Q37436987-5AC079CE-DDF0-43F7-BDBA-494066AF4392

P1476

Q37436987-45C7A7C4-ED00-4FF9-85D7-C6F4B208596E

P2093

Q37436987-D1B40B60-0E43-4DA2-950C-8AE0D6A6A23E

P2860

Q37436987-0CDC926D-166D-49C4-BEFC-59C0117CCAC6

Q37436987-1ADA469A-3DB7-4191-9E71-1E554060B673

Q37436987-3AB37573-35C7-484A-8A5C-F21F7BD78955

Q37436987-3B0DB9A4-CBFB-4541-BC8A-DA2971FBBB0C

Q37436987-48F89992-330B-4218-B85D-0DCB43DB4014

Q37436987-5646EEEE-B38D-4751-90E2-F5407E11F688

Q37436987-5BF62B6E-469B-4333-A9FA-A9F012E19E86

Q37436987-6CD2FB8A-14F6-46B4-B68C-23B9E85E91C0

Q37436987-6E4D99A2-55B4-4AEE-A260-341E7595CCC7

Q37436987-77677ED1-2C3A-41CC-A7F4-92E63ECD9F35

P304

Q37436987-33F68915-FC8B-4A4A-BE58-8DD1118AE079

P31

Q37436987-08D8F774-AC33-4672-920C-80106871115C

P356

Q37436987-B9D18DFF-A4AE-4E85-BE77-AD50CD709FBA

P433

Q37436987-184DF00D-0009-44C4-8CCB-C7449EF9E949

P478

Q37436987-DC35935D-0610-4ED5-B2EF-B920C248FE90

P577

Q37436987-EA8E32A7-B2C8-4B2B-AB45-1B04FB3EE180

P5875

Q37436987-A80AD691-368D-47F0-8BC9-3E9EE2E2DB5C

P698

Q37436987-AA8A05EB-3849-4323-8379-CC21ADC3CF67

P932

Q37436987-E7D5CEDA-D4CA-437D-B507-8B53DC23AF3B

P356

P1433

Asian Journal of Andrology

P1476

PSA screening for prostate cancer: why so much controversy?

@en

P2093

Fernand Labrie

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Cancer statistics, 2013

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Screening and prostate-cancer mortality in a randomized European study

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.

Prostate-cancer mortality at 11 years of follow-up.

Comorbidity and mortality results from a randomized prostate cancer screening trial.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.

Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.

P304

603-607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2013.70

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239074205

http://www.w3.org/2001/XMLSchema#string

P698

23770941

http://www.w3.org/2001/XMLSchema#string

P932

3881639

http://www.w3.org/2001/XMLSchema#string